Ca-A Cancer Journal for Clinicians : Impact Factor & More
eISSN: 1542-4863pISSN: 0007-9235
Share this on:
Key Metrics
CiteScore 
716.2
Impact Factor
>= 25
SNIP
173.93
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Ca-A Cancer Journal for Clinicians Journal Specifications
| Overview | |
| Publisher | WILEY |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 1950 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Ca-A Cancer Journal for Clinicians ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Ca-A Cancer Journal for Clinicians
Radiotherapy followed by adjuvant temozolomide improves survival for patients with aggressive IDH-mutated anaplastic glioma.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Ethical considerations of genetic and genomic testing in pediatric oncology: A narrative review.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Title not available
- 1 Mar 2026
- CA: A Cancer Journal for Clinicians
Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Adding carboplatin to sequential taxane-anthracycline neoadjuvant chemotherapy shows improved event-free and overall survival benefits in premenopausal women with triple-negative breast cancer.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Targeting tumor suppressor gene co-mutations in EGFR-mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Radiotherapy followed by adjuvant temozolomide improves survival for patients with aggressive IDH-mutated anaplastic glioma.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Ethical considerations of genetic and genomic testing in pediatric oncology: A narrative review.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Title not available
- 1 Mar 2026
- CA: A Cancer Journal for Clinicians
Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Adding carboplatin to sequential taxane-anthracycline neoadjuvant chemotherapy shows improved event-free and overall survival benefits in premenopausal women with triple-negative breast cancer.
- 1 Mar 2026
- CA: a cancer journal for clinicians
Targeting tumor suppressor gene co-mutations in EGFR-mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification.
- 1 Mar 2026
- CA: a cancer journal for clinicians
FAQs on Ca-A Cancer Journal for Clinicians
How long has Ca-A Cancer Journal for Clinicians been actively publishing? 
What is the publishing frequency of Ca-A Cancer Journal for Clinicians?
How many articles did Ca-A Cancer Journal for Clinicians publish last year?
What is the eISSN & pISSN for Ca-A Cancer Journal for Clinicians?
What is Citescore for Ca-A Cancer Journal for Clinicians?
What is SNIP score for Ca-A Cancer Journal for Clinicians?
Who is the publisher of Ca-A Cancer Journal for Clinicians?
